Summary:
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Brexpiprazole as Adjunctive Therapy in the Maintenance Treatment of Adults With Major Depressive Disorder
Qualified Participants Must:
Male and female outpatient subjects 18 to 65 years of age
Qualified Participants May Receive:
Compensation for time and travel